There Aren’t Many Benefits to Low-Dose Aspirin for Healthy Older Adults

Researchers say that daily aspirin at low doses increases the risk of bleeding in older adults

What do you do when something you have treated as a received truth turns out to be false? Does it give you a headache?

Go ahead, take an aspirin, but, according to a new study, do not expect the white pill to prevent a heart attack.

An older adult with reasonably good health who takes an aspirin at low doses every day may find that it is more harmful than he believes.

The new study, published in The New England Journal of Medicine, consisted of a clinical trial that included residents of the United States and Australia.

He concluded that a low-dose daily aspirin had no effect on the prolongation of life in healthy elderly people.

It also showed a higher rate of major hemorrhage.

The study did not surprise Dr. Ragavendra Baliga, a cardiologist at Wexner Medical Center at Ohio State University.

“This study confirms what we’ve been doing [the] last few years,” Baliga told Healthline.

He cited a 2015 study that showed serious health problems.

“The benefits do not prevent side effects,” he said.

He noted that patients with diagnosed heart disease still benefit from low-dose aspirin, but that for healthy people, it does not work as a preventative.

What the study uncovered

As of 2010 and for four years, the last trial included more than 19,000 people in Australia and the United States who were 70 or older, or 65 for African-American and Hispanic participants, because their risks of dementia or cardiovascular disease are higher.

None of the participants had cardiovascular disease, dementia or physical disability.

About half of the participants received 100 mg of aspirin in low doses, while the rest received a placebo.

Aspirin had no effect on whether people would be diagnosed with dementia or a disability.

About 90 percent of people who took aspirin survived and did not have a persistent physical disability or dementia.

The same thing happened with approximately 90 percent of the people who took the placebo.

However, the researchers found that people who took aspirin showed an increased risk of bleeding, such as bleeding.

John McNeil, head of the Department of Epidemiology and Preventive Medicine at Monash University in Australia, said in a statement that the study had useful results.

“These findings will help inform prescribing physicians who have not known for a long time whether to recommend aspirin to healthy patients who do not have a clear medical reason to do so,” said McNeil.

“The message to take home from such a complex, large and placebo-controlled study is that healthy older people contemplating the best way to preserve their health are unlikely to benefit from aspirin,” he added.

But bleeding, a well-known side effect of aspirin, was confirmed by the study, with a small increase (3.8 percent) in cases of severe bleeding among those taking aspirin versus (2.8 percent) in those who took the drug. placebo.

“It means that millions of healthy older people around the world who take aspirin at low doses without a medical reason can do it unnecessarily, because the study did not show any overall benefit to compensate for the risk of bleeding,” he said.

While aspirin is still a relatively safe drug, it is not benign and patients should follow their doctor’s advice on low-dose daily use, McNeil concluded.

“This study shows why it is so important to do this type of research so that we can get a more complete picture of the benefits and risks of aspirin among healthy older people,” explained Richard Hodes, director of the National Institute on Aging, in a statement.

The study was conducted in Australia by McNeil and associate professor Robyn Woods of the School of Public Health and Preventive Medicine based at the Alfred Medical Research Campus.

The component of the study conducted in the USA UU It was led by Dr. Anne Murray, professor, and Brenda Kirpach, of the Berman Center for Results and Clinical Research in Minneapolis.

Leave a Reply

Your email address will not be published. Required fields are marked *